Fibroblast Growth Factor-21 as a Therapeutic Agent for Metabolic Diseases

Author： Kharitonenkov Alexei   Shanafelt Armen B.  

Publisher： Adis International

ISSN： 1173-8804

Source： BioDrugs, Vol.22, Iss.1, 2008-01, pp. : 37-44

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Relationship between fibroblast growth factor 21 and thyroid stimulating hormone in healthy subjects without components of metabolic syndrome

By  

Family Medicine and Community Health, Vol. 2, Iss. 3, 2014-01 ,pp. : 1-6

Compuscript

Access to resources Recommend Favorite

Therapeutic Potential of Hepatocyte Growth Factor for Treating Neurological Diseases

By  

Current Drug Therapy, Vol. 6, Iss. 3, 2011-08 ,pp. : 197-206

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Angiogenesis: Potential Role of Basic Fibroblast Growth Factor in Patients with Severe Ischaemic Heart Disease

By Simons M.   Laham R.J.   Post M.   Sellke F.W.  

BioDrugs, Vol. 14, Iss. 1, 2000-07 ,pp. : 13-20

Adis International

Access to resources Recommend Favorite

Targeting Nerve Growth Factor in Pain: What is the Therapeutic Potential?

By Watson Judy J.   Allen Shelley J.   Dawbarn David  

BioDrugs, Vol. 22, Iss. 6, 2008-01 ,pp. : 349-359

Adis International

Access to resources Recommend Favorite

Somatomedin-1 (Recombinant Insulin-Like Growth Factor-1): Clinical Pharmacology and Potential Treatment of Endocrine and Metabolic Disorders

By Laron Z.  

BioDrugs, Vol. 11, Iss. 1, 1999-01 ,pp. : 55-70

Adis International

Access to resources Recommend Favorite